Genprex, Inc.
Clinical trials sponsored by Genprex, Inc., explained in plain language.
-
New gene therapy combo aims to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing a new combination treatment for people with an advanced form of small cell lung cancer. After initial chemotherapy, patients who are stable will receive a new gene therapy drug (quaratusugene ozeplasmid) along with an existing immunotherapy (atezolizumab) to…
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
First systemic gene therapy tested to Re-Sensitize lung cancer to treatment
Disease control Recruiting nowThis study is testing whether adding a new gene therapy called Reqorsa to the standard drug osimertinib can help control advanced lung cancer that has started growing again. The trial is for adults with a specific genetic type of lung cancer (EGFR-mutant) whose cancer progressed …
Phase: PHASE1, PHASE2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC